Cryoport, Inc., a global supply chain solutions provider for the life sciences industry, opened its newest IntegriCell facility in Villers-le-Bouillet, Liege, Belgium. The Center of Excellence is now fully operational and prepared to support the development and commercialization of cell-based therapies with advanced cryopreservation solutions for leukapheresis, a common starting material.
 
IntegriCell is a standardized bioprocessing, cryopreservation and distribution solution for the global cell therapy market. The solution is designed to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality and product stability to support the effective scale up, production and availability of these treatments.
 
This ~13,400 sq. ft., custom-built, GMP-compliant cryopreservation facility expands Cryoport’s capabilities by developing, optimizing and validating cryogenic preservation methods for leukapheresis materials to meet the highest standards for cell-based therapies. The facility has the capacity to cryopreserve over 1,100 leukapheresis products annually. IntegriCell will provide a reliable supply of high-quality, manufacture-ready cryopreserved leukopaks. The IntegriCell Belgium site will transfer these optimized cryopreservation processes to other Cryoport facilities, ensuring consistent quality across clinical and commercial cell-based therapy programs.
 
“Our new IntegriCell Belgium facility extends our global reach and strengthens our ability to deliver consistent, high-quality cryopreservation solutions for the cell therapy community,” said Jerrell Shelton, CEO of Cryoport. “This Center of Excellence, together with our Houston, TX facility, provides the industry with a critical resource to standardize and improve how we preserve cellular starting materials, helping bring transformative therapies to patients more efficiently. With room for future expansion, this facility is designed to adapt and expand with our clients’ and the market’s evolving needs.”